Publication not explained
Read the Original
This page is a summary of: A double-blind, randomized trial, including frequent patient–physician contacts and Ramadan-focused advice, assessing vildagliptin and gliclazide in patients with type 2 diabetes fasting during Ramadan: the STEADFAST study, Vascular Health and Risk Management, May 2014, Taylor & Francis, DOI: 10.2147/vhrm.s64038.
You can read the full text:
The following have contributed to this page